Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
NCT03825289 · University of Utah · PHASE1 · terminated · last registry update 2026-05-14 · Pancreatic cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of Funding” | – | Registry record, University of Utah |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TLR7 in pancreatic cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-05Results posted on the registry: Massachusetts General Hospital, Capecitabine + Hydroxychloroquine (NCT01494155)
- 2026-07-21Results posted on the registry: HonorHealth Research Institute, Paclitaxel protein bound + Gemcitabine (NCT04669197)
- 2026-04-13Also stopped (terminated): Cancer Trials Ireland, Trametinib + Hydroxychloroquine (NCT05518110)
- 2026-01-23Results posted on the registry: Emory University, Gemcitabine + Hydroxychloroquine (NCT04524702)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision